Eloxx Pharmaceuticals, Inc.

ELOX Nasdaq SEC CIK 1035354
Follow Eloxx Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$5.5M −1479.2% vs same quarter last year
EPS, diluted −$0.49 +15.5% vs same quarter last year
Operating cash flow −$4.3M −149.5% vs same quarter last year
Operating income −$6M −1988.8% vs same quarter last year
Net income by quarter
−$1.7M
−$1.9M
−$351K
−$2M
−$3.8M
−$4.5M
−$5.5M
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$80M−$60M−$40M−$20M$0$20MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$6M
FY24$6.4M−$3.1M
FY23$0−$17.1M
FY22-−$36.1M
FY21-−$66.7M
FY20-−$34.6M
FY19-−$50.9M
FY18-−$47.2M
FY17-−$21.2M
FY16-−$9.8M
FY15--
FY14$182.2K−$9.2M
FY13$7.8K−$6.1M
FY12$200K−$5.1M
FY11-−$7.3M
MarginsShare of revenue
  • Operating margin
  • Net margin
−80000%−60000%−40000%−20000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24−38.8%−49.4%
FY23--
FY22--
FY21--
FY20--
FY19--
FY18--
FY17--
FY16--
FY15--
FY14−5019.9%−5062.4%
FY13−59476.9%−78303.4%
FY12−2705.8%−2533.1%
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22−$31.9M
FY21−$35.1M
FY20-
FY19−$39.4M
FY18−$31.6M
FY17−$16.2M
FY16−$8.9M
FY15−$5.7M
FY14−$4.9M
FY13−$3.9M
FY12−$4.4M
FY11−$5.4M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Eloxx Pharmaceuticals
  • Healthcare median
−80000%−60000%−40000%−20000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearEloxx PharmaceuticalsHealthcare median
FY25-−30.6%
FY24−49.4%−47%
FY23-−58%
FY22-−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14−5062.4%−35.5%
FY13−78303.4%−37.1%
FY12−2533.1%−29.1%
FY11-−27.9%